Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-940

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0940 89)

Label for Sacubitril/Valsartan 24 mg/26 mg film-coated tablets, containing 720 tablets. Manufacturer is MSN Pharmaceuticals Inc., Piscataway, NJ, and packaging is by Aphena Pharma, Cookeville, TN. Storage instructions specify 20-25 degrees Celsius, and it is for prescription use only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

A scatter plot chart illustrating the geometric mean ratio and 90% confidence interval for various coadministered drugs with Sacubitril and Valsartan. The chart compares changes in AUC and Cmax relative to reference for drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

A comparative bar chart showing the geometric mean ratio and 90% confidence intervals for AUC and Cmax of sacubitril (LBQ657) and valsartan across various population groups, including renal and hepatic impairment levels, age groups, sex, and racial groups. It visually depicts changes relative to reference values for these subpopulations.*

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

Three Kaplan-Meier plots depict cumulative failure rates over time since randomization (days) in the PARADIGM-HF study. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations; Figure B shows time to occurrence of cardiovascular death; Figure C shows time to first occurrence of heart failure hospitalizations. Each compares Sacubitril and Valsartan versus Enalapril with survival curves and risk tables.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

Chemical structure diagram depicting the molecular structures of Sacubitril and Valsartan, the active ingredients in the combination drug Sacubitril and Valsartan. The image shows detailed atomic arrangements and chemical bonds for both compounds.*

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

A forest plot comparing the hazard ratios and 95% confidence intervals for various subgroups between Sacubitril and Valsartan and Enalapril. Subgroups include age, gender, weight, race, region, NYHA class, eGFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, heart failure history, and ICD presence. The horizontal axis shows hazard ratios where values less than 1 favor Sacubitril and Valsartan and values greater than 1 favor Enalapril.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.